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Abstract
Background: Human paraoxonase 1 (PON1) is an HDL-associated enzyme with anti-oxidant/anti-inflammatory
properties that has been suggested to play an important protective role against coronary heart diseases and
underlying atherogenesis. The common PON1 Q192R polymorphism (rs662, A>G), a glutamine to arginine
substitution at amino acid residue 192, has been analyzed in numerous association studies as a genetic marker for
coronary heart diseases, however, with controversial results.
Findings: To get a better understanding about the pathophysiological function of PON1, we analyzed the
relationships between the Q192R polymorphism, serum paraoxonase activity and serum biomarkers important for
atherogenesis. Genotyping a cohort of 49 healthy German males for the Q192R polymorphism revealed an allele
distribution of 0.74 and 0.26 for the Q and R allele, respectively, typical for Caucasian populations. Presence of the
R192 allele was found to be associated with a significantly increased paraoxonase enzyme activity of 187.8 ± 11.4
U/l in comparison to the QQ192 genotype with 60.5 ± 4.9 U/l. No significant differences among the genotypes
were found for blood pressure, asymmetric dimethylarginine, LDL, HDL, triglycerides, and cholesterol. As expected,
MIP-2 alpha a cytokine rather not related to atherosclerosis is not affected by the PON1 polymorphism. In contrast
to that, the pro-inflammatory cytokine TNF-alpha is enhanced in R192 carriers (163.8 ± 24.7 pg/ml vs 94.7 ± 3.2 pg/
ml in QQ192 carriers).
Conclusions: Our findings support the hypothesis that the common PON1 R192 allele may be a genetic risk factor
for atherogenesis by inducing chronic low-grade inflammation.
Introduction
Paraoxonase 1 (PON1) is a calcium-dependent enzyme
exhibiting esterase, lactonase and peroxidase activity. It
accepts a broad range of substrates including organo-
phosphates, diverse lactones and lipid peroxides and has
been studied for its ability to breakdown pesticides and
nerve gases. PON1 is a glycoprotein of about 45 kDa
that is predominantly synthesized by the liver, from
where it is distributed to other tissues, mainly to serum
[1,2]. In serum, PON1 is associated with high-density-
lipoprotein (HDL) particles [3]. HDL-associated PON1
has been frequently shown to have anti-oxidant and
anti-inflammatory potential ma i n l yb yp r o t e c t i n gl i p i d s
of HDLs and low-density lipoproteins (LDL) from oxida-
tive modifications [1,2]. Most likely, these protective
effects depend on the peroxidase and esterase activity of
PON1 allowing the detoxification of oxidized molecules
such as phospholipids and lipid hydroperoxides [4,5].
Cardiovascular diseases and underlying atherosclerosis
are associated with oxidative stress and inflammation.
Hence, serum PON1 is suggested to contribute to the
established anti-atherogenic function of HDLs which is,
at least partly, attributable to their anti-oxidative proper-
ties [1,2,6].
This notion is further supported by animal model stu-
dies using PON1 knock out and transgenic PON1 over-
expressing mice. HDLs of PON1
-/- knock-out mice were
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from control mice [7]. On the other hand, increased
PON1 content in transgenic mice overexpressing murine
or human PON1 resulted in HDLs that were more pro-
tected from lipid peroxidation [8,9]. Moreover, PON1
deficiency in mice resulted in elevated levels of oxidative
stress and endothelial adhesion molecules [10]. Accord-
ingly, PON1
-/- animals exhibited increased susceptibility
to the development of large atherosclerotic lesions on a
high-fat diet [7], whereas mice overexpressing human
PON1 exhibited decreased atherosclerotic lesion sizes
when fed an atherogenic diet [8,9].
The human PON1 gene is located on the long arm of
chromosome 7 between q21 and q22. Two common
coding region polymorphisms occur: a glutamine to
arginine substitution at position 192 (Q192R) which
affects PON1 enzyme activity and is analyzed in this
study, and a leucine to methionine substitution at posi-
tion 55 (L55M) [11]. PON1 gene polymorphisms have
been examined with respect to their association to var-
ious human diseases including coronary heart disease
(CHD), Parkinson’s disease, type 2 diabetes and inflam-
matory bowel disease [12,13]. Most studies focused on
the anti-oxidant/anti-inflammatory properties of PON1
in association with the development of atherosclerosis
and the role of the Q192R polymorphism as a genetic
marker for CHD. However, the results reported so far
are controversial, some indicating an association
between the Q192R polymorphism and atherosclerosis
and CHD risk, while others do not as reviewed in
[12,13].
In the present study, we have analyzed the influence
of the PON1 Q192R polymorphism on serum lipids and
inflammatory biomarkers in a cohort of 49 healthy male
individuals to get a better understanding of the role of
the PON1 Q192R polymorphism in the development of
atherosclerosis and CHD.
Materials and methods
Participants and study design
The cohort of 53 healthy males investigated in the pre-
sent study has been recently described [14]. In short,
based on clinical laboratory tests, the participants aged
b e t w e e n2 1a n d4 8h a da na v e r a g eB o d yM a s sI n d e x
(BMI) of 24.1 ± 2.5 and fulfilled four criteria: (i) no his-
tory of gastrointestinal, hepatic, cardiovascular or renal
disease, (ii) no supplemental vitamin use for ≥ 2w e e k s
before the start of the study, (iii) non- or occasional
smoking (≤ 3 cigarettes/day), and (iv) perpetuation of
usual nutrition habits. Fasting blood samples were taken
from each participant for genotyping, PON1 enzyme
activity determination and inflammatory biomarker ana-
lyses. The study was approved by the ethics committee
of the Medical Faculty of Kiel University, Germany,
(permission number A121/07) and was conformed to
Helsinki Declaration. All volunteers gave written
informed consent prior to participation.
Genotyping
G e n o m i cD N Aw a si s o l a t e df r o mw h o l eb l o o ds a m p l e s .
Genotyping of the PON1 Single Nucleotide Polymorph-
ism (SNP) A/A, A/G, G/G (rs662) responsible for the
Q192R substitutions was performed by using the Taq-
Man system. Fluorescence was measured with ABI
Prism 7900 HT sequence detection system (ABI, Foster
City, USA).
PON enzyme activity assay
PON enzyme activity was determined spectrophotome-
trically in plasma samples following the protocol
described in [15]. Briefly, the rate of hydrolysis of para-
oxon (diethyl-p-nitrophenyl phosphatate; Supelco) was
measured by monitoring the increase of absorbance at
405 nm using 100 mM Tris-HCl (pH 8.0), 1 mM para-
oxon and 2 mM CaCl2. One unit of PON activity is
defined as 1 nmol of 4-nitrophenol formed per minute
at 20 °C under standard assay conditions (ε = 17600 M
-
1 cm
-1).
Serum biomarkers
Supernatants of whole blood samples were measured
with commercially available ELISA kits for TNF-alpha,
M C P - 1( R & DS y s t e m s ,M i n n e a p o l i s ,M N ) ,o x L D L
(KAMIYA Biomedical Company, Seattle, USA), asym-
metric dimethylarginine (ADMA) (DLD Diagnostika,
Hamburg, Germany) and MIP-2-alpha (Promocell,
Heidelberg, Germany). Optical density was read on a
microplate reader (Spectramax
® 190, Molecular
Devices). Laboratory measurements including serum
lipid concentrations have been described previously [16].
Statistical analysis
Results are displayed as means ± SEM. Data were ana-
lyzed by an unpaired two-sided Student’s t-test (Micro-
soft Excel Version 2003 or GraphPad Prism 4.0
software). P-values < 0.05 were considered statistically
significant.
Results
Genotype distribution and basic characteristics
Genotype analysis of the PON1 Q192R polymorphism
(rs662, A>G) of 53 male volunteers revealed 25 homo-
zygous for Q/Q (51%), 23 heterozygous for Q/R (47%)
and 1 homozygous for R/R (2%), while 4 probes failed
genotyping. Because of the small incidence, in further
studies the G/G genotype (phenotype R/R) was com-
bined with the A/G genotype (phenotype Q/R) group.
Basic characteristics of the cohort have been recently
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(30.13 ± 6.71 years), weight (79.11 ± 10.17 kg), height
(1.81 ± 0.06 m), BMI (24.12 ± 2.50 kg/m
2)a n df a s t i n g
glucose level (86.47 ± 10.68 mg/dl) as well as for the
kidney and liver parameters creatinine (1.05 ± 0.10 m/
dl), aspartate aminotransferase (30.09 ± 8.67 U/l), glu-
tamate pyruvate transaminase (37.79 ± 14.73 U/l) and
g-glutamyl transpeptidase (20.49 ± 10.36 U/l) were in
accordance with the inclusion criteria of the study and
show values within the physiological range for healthy
men.
Effect of the Q192R polymorphism on PON1 activity
PON1 enzyme activity was found to be significantly ele-
vated in the serum of Q/R and R/R individuals with a
mean value of 187.8 ± 11.4 U/l, when compared to the
Q/Q group having a mean value of 60.5 ± 4.9 U/l (p <
0.001; unpaired two-sided Student’s t-test) (Figure 1).
These data confirm previous studies that have demon-
strated a similar effect of the Q192R polymorphism on
serum PON1 activity [4,15].
Effect of the Q192R polymorphism on blood pressure and
ADMA
Subsequently we analyzed a possible association between
the Q192R polymorphism and blood pressure. However,
no significant differences for blood pressure and ADMA
levels, a blood pressure biomarker, were found between
the Q/Q and the combined Q/R + R/R group with
mean values of 82.5 ± 2.0 versus 82.9 ± 1.9 for diastolic
and 125.0 ± 2.4 versus 128.0 ± 2.6 for systolic pressure
as well as 0.96 ± 0.05 versus 0.98 ± 0.07 μmol/l for
ADMA.
Effect of the Q192R polymorphism on serum lipoproteins
and lipids
The Q192R polymorphism had no significant effect on
HDL (51.7 ± 2.8 versus 50.8 ± 2.4 mg/dl), LDL (95.8 ± 5.7
versus 92.8 ± 6.1 mg/dl), triglycerides (TG) (91.0 ± 8.1 ver-
sus 102.9 ± 11.6 mg/dl) and cholesterol (165.7 ± 5.1 versus
164.1 ± 6.7 mmol/l). In addition, we found a slight but not
significant increase in the oxLDL levels for the Q/R + R/R
group with a mean of 21.7 ± 2.8 U/ml compared to Q/Q
individuals with a mean value of 17.8 ± 3.0 U/ml.
Effect of the Q192R polymorphism on inflammatory
biomarkers
Finally, we analyzed the effect of the Q192R polymorph-
ism on the inflammatory biomarkers TNF-alpha, MCP-1
and MIP-2-alpha. As shown in Figure 2A, the mean
level of TNF-alpha for the Q/Q group was found to be
94.7 ± 3.2 pg/ml. In the sera of Q/R and R/R individuals
the respective level was significantly enhanced with a
mean value of 163.8 ± 24.7 pg/ml (p = 0.007; unpaired
two-sided Student’s t-test). Furthermore, the inflamma-
tory biomarker MCP-1 was slightly but not significantly
enhanced in Q/R and R/R individuals when compared
with the Q/Q group (202.0 ± 30.7 versus 173.0 ± 11.2
ng/ml) (Figure 2B). In contrast to that, MIP-2-alpha
levels were not affected by the Q192R polymorphism
(258.2 ± 13.7 versus 248.1 ± 12.9 pg/ml; Figure 2C).
Discussion
The role of the PON1 Q192R polymorphism in cardio-
vascular diseases is still under debate [1,2,12,13]. In the
present study, genotyping of a cohort of 49 German
males revealed a frequency of 0.74 for the Q192 allele
confirming previous reports on Western populations
with Caucasian origin [17-20]. Moreover, we found that
t h eo c c u r r e n c eo ft h eR 1 9 2a l l e l el e dt oa ne l e v a t e d
serum paraoxonase activity which is also in good accor-
dance with previously published data on the Q and R
allozymes [21,22]. In this regard it is noteworthy that
paraoxon represents a non-natural substrate and that
the natural substrate(s) of PON1 has/have not been
identified so far [2]. Consequently, it is not a contradic-
tion that elevated specific paraoxonase activities of
PON1 allozymes have been demonstrated to be nega-
tively correlated with their antioxidant capacity in
H D L s ,i . e .p r o t e c t i n gL D L sa g a inst oxidation, reversing
the biological effects of oxidised LDLs and preserving
the function of HDLs [13,21,22]. Since the oxidation of
LDL and the accompanied formation of foam cell layers
are thought to represent crucial steps in the initiation
process of atherosclerosis [23,24], an enhanced antioxi-
dant activity of HDLs has been suggested to prevent
atherosclerosis and CHD [1,2]. Accordingly, a low-active
paraoxonase allele such as PON1 Q192 should protect
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Figure 1 Effect of the PON1 Q192R polymorphism on serum
PON1 enzyme activity. PON1 activity was determined in the sera
of Q/Q (n = 25) and Q/R+R/R (n = 24) male individuals under
standard assay conditions using paraoxon as substrate. Data
represent means ± SEM (*** p ≤ 0.001).
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sponding high-active R192 allele. Although such an
association has been found in some studies
[17-19,25-31], no relationship has been revealed by
others [20,32-38]. Recent meta-analyses suggested a
weak association between the PON1 Q192R polymorph-
i s ma n dC H Dr i s k[ 3 9 ] ,h o w e v e r ,n oo ro n l yap o p u l a -
tion-specific effect of the R192 allele on human
longevity [40]. Here we addressed the question whether
the Q192R polymorphism and the related differences in
PON1 activity are linked to changes in biomarkers indi-
cative for a pro-atherogenic status.
Our analyses revealed that PON1 genotypes are not
associated with alterations in blood pressure and
ADMA levels, elevation of both are linked with athero-
sclerosis [41]. Moreover, there were no differences in
the serum lipid profiles including TG, HDL, LDL and
cholesterol, except for slightly but not significantly
enhanced oxLDL levels. Similar results for TG, HDL,
LDL and cholesterol have been reported previously
[19,20,25,29,31-34,36-38], whereas a few studies found a
more pro-atherogenic serum lipid and/or lipoprotein
pattern in association with the R192 allele [35,42]. The
principal finding of this study is that the frequency of
the low-antioxidant R192 allele is associated with signifi-
cantly increased levels of the pro-inflammatory cytokine
TNF-alpha. Since chronic low grade alterations of
inflammatory markers are known to be associated with
increased atherogenic risk [43], elevated R192 allele-
dependent TNF-alpha levels may thus represent a puta-
tive risk marker.
Only recently, it has been demonstrated that adeno-
virus-based overexpression of human PON1 in apolipo-
protein E knock-out mice caused enhanced serum anti-
oxidative and anti-inflammatory capabilities reflected
among other factors by decreased TNF-alpha levels [44].
Hence, enhanced PON1 antioxidant capacity was found
to be associated with reduced TNF-alpha levels, prob-
ably protective against atherosclerosis. Considering the
anti-oxidant property of HDL-associated PON1, it is
intriguing to speculate that low amounts of serum
PON1 or low-anti-oxidant PON1 alleles such as R192
lead to elevated levels of reactive oxygen species in this
way triggering the redox-sensitive NfkappaB signaling
pathway that is known to stimulate TNF-alpha expres-
sion. However, further mechanistic investigations are
necessary to decipher this proposed PON1 TNF-alpha
relationship. It is remarkable that, in turn, enhanced
TNF-alpha levels have been shown to down-regulate
PON1 expression in murine and human hepatoma cell
l i n e sa sw e l la sin vivo in mice, most probably via an
NF-kappaB- and nuclear receptor peroxisome prolifera-
tor-activated receptor-alpha (PPAR-alpha)-dependent
mechanism thereby diminishing the antioxidant and
anti-atherogenic activity of HDLs [45,46]. Moreover, a
TNF-alpha antagonist therapy in rheumatoid arthritis
patients led to enhanced PON1 levels concurrent with
elevated anti-oxidative capacities of HDLs and lowered
inflammatory status [47]. Interestingly, anti-TNF-alpha
therapy response was found to be associated with SNPs
in the PON1 locus [48] and a recent case-control study
on atherosclerosis in rheumatoid arthritis found a
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Figure 2 Effect of the PON1 Q192R polymorphism on inflammatory biomarkers. (A) TNF-alpha, (B) MCP-1 and (C) MIP-2-alpha levels were
determined in the sera of Q/Q (n = 25) and Q/R+R/R (n = 24) male subjects. Data represent means ± SEM (** p ≤ 0.01).
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Page 4 of 6correlation between PON-1a c t i v i t ya n ds e r u mT N F -
alpha and IL-6 levels [49], emphasizing the close regula-
tory interrelation between PON1 activity and TNF-alpha
levels.
In addition to TNF alpha, we found that levels of a
second pro-inflammatory cytokine MCP-1 were slightly
although not significantly enhanced in R192 carriers
that usually express PON1 allozymes with less antioxi-
dant capacity. MCP-1 expression and secretion of
endothelial cells are known to be induced by oxidized
LDL and accordingly, are thought to represent a crucial
step in the initial phase of the inflammatory processes
in atherosclerosis [43]. Consistent with its anti-oxidant
function that leads to reduced lipid peroxidation, PON1
has been demonstrated to attenuate MCP-1 expression
of cultured endothelial cells [50]. In good accordance
with that are data on HDLs isolated from wild type and
PON1 knock-out mice. In a human endothelial cell cul-
ture model PON1
-/- HDLs exhibited significantly less
antioxidant capacity accompanied with elevated MCP-1
levels, hence, linking PON1 deficiency to lipid hydroper-
oxide-triggered expression of pro-inflammatory MCP-1
[7]. Since the amount of MIP-2 alpha, a cytokine rather
not related to atherosclerosis, is not affected by PON1
polymorphism, the observed changes of TNF-alpha and
MCP-1 levels observed in the current study are most
likely specific.
Conclusion
Our data indicate that the low-antioxidant PON1 R192
allele is associated with increased pro-inflammatory
cytokines known to be involved in the initiation process
of atherosclerosis. However, our finding needs to be
confirmed in further studies and especially in larger
study population.
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tide polymorphism; TG: triglycerides.
Acknowledgements and Funding
This work was supported by KANEKA Corporation, Japan.
Author details
1Institute of Human Nutrition and Food Science, Molecular Prevention,
Christian-Albrechts-University of Kiel, Heinrich-Hecht-Platz 10, 24118 Kiel,
Germany.
2Institute of Human Nutrition and Food Science, Food Science,
Christian-Albrechts-University of Kiel, Hermann-Rodewald-Straße 6, 24118
Kiel, Germany.
Authors’ contributions
KL analysed the data and wrote the manuscript. CS participated in the
design of the study, acquired and analysed data. CBS performed enzyme
assays. CK carried out genotyping studies. GR participates in the design of
the study and critically revised the manuscript. FD conceived and designed
the study, analysed the data and wrote the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 14 February 2011 Accepted: 10 May 2011
Published: 10 May 2011
References
1. Ng CJ, Shih DM, Hama SY, Villa N, Navab M, Reddy ST: The paraoxonase
gene family and atherosclerosis. Free Radic Biol Med 2005, 38(2):153-163.
2. Precourt LP, Amre D, Denis MC, Lavoie JC, Delvin E, Seidman E, Levy E: The
three-gene paraoxonase family: Physiologic roles, actions and regulation.
Atherosclerosis 2011, 214(1):20-36.
3. Mackness MI, Hallam SD, Peard T, Warner S, Walker CH: The separation of
sheep and human serum “A"-esterase activity into the lipoprotein
fraction by ultracentrifugation. Comp Biochem Physiol B 1985,
82(4):675-677.
4. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, Billicke S,
Draganov D, Rosenblat M: Human serum paraoxonases (PON1) Q and R
selectively decrease lipid peroxides in human coronary and carotid
atherosclerotic lesions: PON1 esterase and peroxidase-like activities.
Circulation 2000, 101(21):2510-2517.
5. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM,
Navab M: Protective effect of high density lipoprotein associated
paraoxonase. Inhibition of the biological activity of minimally oxidized
low density lipoprotein. J Clin Invest 1995, 96(6):2882-2891.
6. Soran H, Younis NN, Charlton-Menys V, Durrington P: Variation in
paraoxonase-1 activity and atherosclerosis. Curr Opin Lipidol 2009,
20(4):265-274.
7. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE,
Costa LG, Fogelman AM, et al: Mice lacking serum paraoxonase are
susceptible to organophosphate toxicity and atherosclerosis. Nature
1998, 394(6690):284-287.
8. Oda MN, Bielicki JK, Ho TT, Berger T, Rubin EM, Forte TM: Paraoxonase 1
overexpression in mice and its effect on high-density lipoproteins.
Biochem Biophys Res Commun 2002, 290(3):921-927.
9. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM:
Decreased atherosclerotic lesion formation in human serum
paraoxonase transgenic mice. Circulation 2002, 106(4):484-490.
10. Ng DS, Chu T, Esposito B, Hui P, Connelly PW, Gross PL: Paraoxonase-1
deficiency in mice predisposes to vascular inflammation, oxidative
stress, and thrombogenicity in the absence of hyperlipidemia. Cardiovasc
Pathol 2008, 17(4):226-232.
11. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE:
The molecular basis of the human serum paraoxonase activity
polymorphism. Nat Genet 1993, 3(1):73-76.
12. Furlong CE, Suzuki SM, Stevens RC, Marsillach J, Richter RJ, Jarvik GP,
Checkoway H, Samii A, Costa LG, Griffith A, et al: Human PON1, a
biomarker of risk of disease and exposure. Chem Biol Interact 187(1-
3):355-361.
13. Li HL, Liu DP, Liang CC: Paraoxonase gene polymorphisms, oxidative
stress, and diseases. J Mol Med 2003, 81(12):766-779.
14. Schmelzer C, Niklowitz P, Okun JG, Haas D, Menke T, Döring F: Ubiquinol-
induced gene expression signatures are translated into reduced
erythropoiesis and LDL cholesterol levels in humans. IUBMB Life 2011,
63(1):42-48.
15. Boesch-Saadatmandi C, Rimbach G, Schrader C, Kofler BM, Armah CK,
Minihane AM: Determinants of paraoxonase activity in healthy adults.
Mol Nutr Food Res 54(12):1842-1850.
16. Egert S, Wolffram S, Bosy-Westphal A, Boesch-Saadatmandi C, Wagner AE,
Frank J, Rimbach G, Mueller MJ: Daily quercetin supplementation dose-
dependently increases plasma quercetin concentrations in healthy
humans. J Nutr 2008, 138(9):1615-1621.
17. Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, Cohen N,
Morabia A, Passa P, Froguel P: Gln-Arg192 polymorphism of paraoxonase
and coronary heart disease in type 2 diabetes. Lancet 1995,
346(8979):869-872.
Lüersen et al. BMC Research Notes 2011, 4:141
http://www.biomedcentral.com/1756-0500/4/141
Page 5 of 618. Serrato M, Marian AJ: A variant of human paraoxonase/arylesterase
(HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest
1995, 96(6):3005-3008.
19. Regieli JJ, Jukema JW, Doevendans PA, Zwinderman AH, Kastelein JJ,
Grobbee DE, van der Graaf Y: Paraoxonase variants relate to 10-year risk
in coronary artery disease: impact of a high-density lipoprotein-bound
antioxidant in secondary prevention. J Am Coll Cardiol 2009,
54(14):1238-1245.
20. Turban S, Fuentes F, Ferlic L, Brugada R, Gotto AM, Ballantyne CM,
Marian AJ: A prospective study of paraoxonase gene Q/R192
polymorphism and severity, progression and regression of coronary
atherosclerosis, plasma lipid levels, clinical events and response to
fluvastatin. Atherosclerosis 2001, 154(3):633-640.
21. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN: Effect of the
human serum paraoxonase 55 and 192 genetic polymorphisms on the
protection by high density lipoprotein against low density lipoprotein
oxidative modification. FEBS Lett 1998, 423(1):57-60.
22. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M,
Erogul J, Hsu C, Dunlop C, La Du B: Paraoxonase active site required for
protection against LDL oxidation involves its free sulfhydryl group and
is different from that required for its arylesterase/paraoxonase activities:
selective action of human paraoxonase allozymes Q and R. Arterioscler
Thromb Vasc Biol 1998, 18(10):1617-1624.
23. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE,
Butler S, Witztum JL, Steinberg D: Evidence for the presence of oxidatively
modified low density lipoprotein in atherosclerotic lesions of rabbit and
man. J Clin Invest 1989, 84(4):1086-1095.
24. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond
cholesterol. Modifications of low-density lipoprotein that increase its
atherogenicity. N Engl J Med 1989, 320(14):915-924.
25. Sanghera DK, Saha N, Aston CE, Kamboh MI: Genetic polymorphism of
paraoxonase and the risk of coronary heart disease. Arterioscler Thromb
Vasc Biol 1997, 17(6):1067-1073.
26. Tobin MD, Braund PS, Burton PR, Thompson JR, Steeds R, Channer K,
Cheng S, Lindpaintner K, Samani NJ: Genotypes and haplotypes
predisposing to myocardial infarction: a multilocus case-control study.
Eur Heart J 2004, 25(6):459-467.
27. Lakshmy R, Ahmad D, Abraham RA, Sharma M, Vemparala K, Das S,
Reddy KS, Prabhakaran D: Paraoxonase gene Q192R & L55M
polymorphisms in Indians with acute myocardial infarction & association
with oxidized low density lipoprotein. Indian J Med Res 131:522-529.
28. Gluba A, Pietrucha T, Banach M, Piotrowski G, Rysz J: The role of
polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/
Cys in PON2) in the modulation of cardiovascular risk: a pilot study.
Angiology 61(2):157-165.
29. Odawara M, Tachi Y, Yamashita K: Paraoxonase polymorphism (Gln192-
Arg) is associated with coronary heart disease in Japanese noninsulin-
dependent diabetes mellitus. J Clin Endocrinol Metab 1997,
82(7):2257-2260.
30. Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, Watanabe G,
Ishikawa K, Ikeda Y: A 192Arg variant of the human paraoxonase
(HUMPONA) gene polymorphism is associated with an increased risk for
coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol
1997, 17(12):3565-3569.
31. Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, Hamada C,
Kurihara Y, Shindo T, Oh-hashi Y, et al: Evidence for association between
paraoxonase gene polymorphisms and atherosclerotic diseases.
Atherosclerosis 2000, 149(2):435-442.
32. Antikainen M, Murtomaki S, Syvanne M, Pahlman R, Tahvanainen E,
Jauhiainen M, Frick MH, Ehnholm C: The Gln-Arg191 polymorphism of the
human paraoxonase gene (HUMPONA) is not associated with the risk of
coronary artery disease in Finns. J Clin Invest 1996, 98(4):883-885.
33. Rice GI, Ossei-Gerning N, Stickland MH, Grant PJ: The paraoxonase Gln-Arg
192 polymorphism in subjects with ischaemic heart disease. Coron Artery
Dis 1997, 8(11-12):677-682.
34. Herrmann SM, Blanc H, Poirier O, Arveiler D, Luc G, Evans A, Marques-
Vidal P, Bard JM, Cambien F: The Gln/Arg polymorphism of human
paraoxonase (PON 192) is not related to myocardial infarction in the
ECTIM Study. Atherosclerosis 1996, 126(2):299-303.
35. Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F,
Campagna F, Cantini R, Campa PP, Ricci G, Arca M: The gln-Arg192
polymorphism of human paraoxonase gene is not associated with
coronary artery disease in italian patients. Arterioscler Thromb Vasc Biol
1998, 18(10):1611-1616.
36. Ko YL, Ko YS, Wang SM, Hsu LA, Chang CJ, Chu PH, Cheng NJ, Chen WJ,
Chiang CW, Lee YS: The Gln-Arg 191 polymorphism of the human
paraoxonase gene is not associated with the risk of coronary artery
disease among Chinese in Taiwan. Atherosclerosis 1998, 141(2):259-264.
37. Suehiro T, Nakauchi Y, Yamamoto M, Arii K, Itoh H, Hamashige N,
Hashimoto K: Paraoxonase gene polymorphism in Japanese subjects
with coronary heart disease. Int J Cardiol 1996, 57(1):69-73.
38. Aubo C, Senti M, Marrugat J, Tomas M, Vila J, Sala J, Masia R: Risk of
myocardial infarction associated with Gln/Arg 192 polymorphism in the
human paraoxonase gene and diabetes mellitus. The REGICOR
Investigators. Eur Heart J 2000, 21(1):33-38.
39. Wang M, Lang X, Zou L, Huang S, Xu Z: Four genetic polymorphisms of
paraoxonase gene and risk of coronary heart disease: a meta-analysis
based on 88 case-control studies. Atherosclerosis 214(2):377-385.
40. Caliebe A, Kleindorp R, Blanche H, Christiansen L, Puca AA, Rea IM,
Slagboom E, Flachsbart F, Christensen K, Rimbach G, et al: No or only
population-specific effect of PON1 on human longevity: a
comprehensive meta-analysis. Ageing Res Rev 2010, 9(3):238-244.
41. Boger RH: Asymmetric dimethylarginine, an endogenous inhibitor of
nitric oxide synthase, explains the “L-arginine paradox” and acts as a
novel cardiovascular risk factor. J Nutr 2004, 134(10 Suppl):2842S-2847S,
discussion 2853S.
42. Hegele RA, Brunt JH, Connelly PW: A polymorphism of the paraoxonase
gene associated with variation in plasma lipoproteins in a genetic
isolate. Arterioscler Thromb Vasc Biol 1995, 15(1):89-95.
43. Braunersreuther V, Mach F, Steffens S: The specific role of chemokines in
atherosclerosis. Thromb Haemost 2007, 97(5):714-721.
44. Zhang C, Peng W, Wang M, Zhu J, Zang Y, Shi W, Zhang J, Qin J: Studies
on protective effects of human paraoxonases 1 and 3 on atherosclerosis
in apolipoprotein E knockout mice. Gene Ther 17(5):626-633.
45. Kumon Y, Suehiro T, Ikeda Y, Hashimoto K: Human paraoxonase-1 gene
expression by HepG2 cells is downregulated by interleukin-1beta and
tumor necrosis factor-alpha, but is upregulated by interleukin-6. Life Sci
2003, 73(22):2807-2815.
46. Han CY, Chiba T, Campbell JS, Fausto N, Chaisson M, Orasanu G, Plutzky J,
Chait A: Reciprocal and coordinate regulation of serum amyloid A versus
apolipoprotein A-I and paraoxonase-1 by inflammation in murine
hepatocytes. Arterioscler Thromb Vasc Biol 2006, 26(8):1806-1813.
47. Popa C, van Tits LJ, Barrera P, Lemmers HL, van den Hoogen FH, van
Riel PL, Radstake TR, Netea MG, Roest M, Stalenhoef AF: Anti-inflammatory
therapy with tumour necrosis factor alpha inhibitors improves high-
density lipoprotein cholesterol antioxidative capacity in rheumatoid
arthritis patients. Ann Rheum Dis 2009, 68(6):868-872.
48. Liu C, Batliwalla F, Li W, Lee A, Roubenoff R, Beckman E, Khalili H, Damle A,
Kern M, Furie R, et al: Genome-wide association scan identifies candidate
polymorphisms associated with differential response to anti-TNF
treatment in rheumatoid arthritis. Mol Med 2008, 14(9-10):575-581.
49. Kerekes G, Szekanecz Z, Der H, Sandor Z, Lakos G, Muszbek L, Csipo I,
Sipka S, Seres I, Paragh G, et al: Endothelial dysfunction and
atherosclerosis in rheumatoid arthritis: a multiparametric analysis using
imaging techniques and laboratory markers of inflammation and
autoimmunity. J Rheumatol 2008, 35(3):398-406.
50. Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M: Paraoxonase-1
inhibits oxidised LDL-induced MCP-1 production by endothelial cells.
Biochem Biophys Res Commun 2004, 318(3):680-683.
doi:10.1186/1756-0500-4-141
Cite this article as: Lüersen et al.: Paraoxonase 1 polymorphism Q192R
affects the pro-inflammatory cytokine TNF-alpha in healthy males. BMC
Research Notes 2011 4:141.
Lüersen et al. BMC Research Notes 2011, 4:141
http://www.biomedcentral.com/1756-0500/4/141
Page 6 of 6